Cai and colleagues showed that the mRNA level of FXR in patients with cholelithiasis was lower than that in control individuals (21), suggesting that the inhibition of FXR signaling is very likely to promote the onset of CGS. The gene discussed is NR1H4; the disease is cholelithiasis.